Cargando…

Maximum Plasma Concentration of Lenvatinib Is Useful for Predicting Thrombocytopenia in Patients Treated for Hepatocellular Carcinoma

BACKGROUND: Although lenvatinib treatment has a favorable efficacy for unresectable hepatocellular carcinoma (HCC), it is associated with adverse events (AEs) that must be closely monitored and managed. Thrombocytopenia is one of the major AEs. The aim of this study was to clarify whether thrombocyt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Endo, Mizuki, Honda, Koichi, Saito, Tomoko, Shiraiwa, Ken, Sueshige, Yoshio, Tokumaru, Tomoko, Iwao, Masao, Tokoro, Masanori, Arakawa, Mie, Tanaka, Ryota, Tatsuta, Ryosuke, Seike, Masataka, Itoh, Hiroki, Murakami, Kazunari
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elmer Press 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8577601/ https://www.ncbi.nlm.nih.gov/pubmed/34804279 http://dx.doi.org/10.14740/wjon1399

Ejemplares similares

Supplementation of branched-chain amino acids decreases fat accumulation in the liver through intestinal microbiota-mediated production of acetic acid
por: Iwao, Masao, et al.
Publicado: (2020)

α‐Tocopherol suppresses hepatic steatosis by increasing CPT‐1 expression in a mouse model of diet‐induced nonalcoholic fatty liver disease
por: Tokoro, Masanori, et al.
Publicado: (2020)

Effect of S‐1 on blood levels of phenobarbital and phenytoin: A case report
por: Shiraiwa, Ken, et al.
Publicado: (2021)

A case of improvement of clozapine-induced low leukocyte counts by adenine, cepharanthin and ninjin-yoei-to in a patient with treatment-resistant schizophrenia
por: Kamei, Shintaro, et al.
Publicado: (2021)

Serum MMP3 Correlated With IL1β Messenger RNA Expressions of Peripheral Blood Mononuclear Cells in Patients With Relapsing Polychondritis With Respiratory Involvement
por: Shimizu, Jun, et al.
Publicado: (2021)

Response to lenvatinib and pembrolizumab combination therapy in pembrolizumab-pretreated relapsed endometrial cancer
por: Mimura, Kaito, et al.
Publicado: (2022)

Lenvatinib for Anaplastic Thyroid Cancer
por: Tahara, Makoto, et al.
Publicado: (2017)

Association between MR-proADM concentration and treatment intensity of antihypertensive agents in chronic kidney disease patients with insufficient blood pressure control
por: Iwao, Motoshi, et al.
Publicado: (2021)

Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Treatment Optimization for Maximum Clinical Benefit
por: Wirth, Lori J, et al.
Publicado: (2022)

Tocilizumab-induced mucosal injury in the terminal ileum mimicking intestinal Behçet’s disease: A case report
por: Ozaka, Sotaro, et al.
Publicado: (2023)

Sustained suppression of enterohepatic circulation of mycophenolic acid by antimicrobial‐associated diarrhea in a kidney transplant recipient with Crohn's disease: A case report
por: Tanaka, Ryota, et al.
Publicado: (2022)

Acute Cholecystitis Associated with Eosinophilic Granulomatosis with Polyangiitis That Responded to Glucocorticoid Therapy
por: Ozaka, Sotaro, et al.
Publicado: (2022)

Using tsunami deposits to determine the maximum depth of benthic burrowing
por: Seike, Koji, et al.
Publicado: (2017)

Validation of a Liquid Chromatography-Tandem Mass Spectrometric Assay for Quantitative Analysis of Lenvatinib in Human Plasma
por: Ogawa-Morita, Tomoko, et al.
Publicado: (2017)

Effect of Lenvatinib treatment on the cell cycle and microRNA profile in hepatocellular carcinoma cells
por: Nakahara, Mai, et al.
Publicado: (2022)

Acquired Factor V Inhibitor Complicated with Immune Thrombocytopenia
por: Mima, Fuka, et al.
Publicado: (2021)

Immune Thrombocytopenia in a Child with T Cell Lymphoblastic Lymphoma
por: Tokeji, Kayo, et al.
Publicado: (2016)

Successful determination of imatinib re‐administration dosage by therapeutic drug monitoring in a case of chronic myeloid leukemia initiating dialysis for acute renal dysfunction
por: Nakahara, Ryosuke, et al.
Publicado: (2021)

UHPLC–MS/MS method for simultaneous quantification of doripenem, meropenem, ciprofloxacin, levofloxacin, pazufloxacin, linezolid, and tedizolid in filtrate during continuous renal replacement therapy
por: Kai, Makoto, et al.
Publicado: (2022)

Repeated Perforation of the Gallbladder in a Patient with Hepatocellular Carcinoma Receiving Lenvatinib
por: Honda, Shuya, et al.
Publicado: (2019)

Interaction between Pirenzepine and Ninjinto, a Traditional Japanese Herbal Medicine, on the Plasma Gut-Regulated Peptide Levels in Humans
por: Sato, Yuhki, et al.
Publicado: (2013)

Impact of lenvatinib on renal function compared to sorafenib for unresectable hepatocellular carcinoma
por: Sasaki, Ryu, et al.
Publicado: (2022)

Influence of CYP3A4/5 and ABC transporter polymorphisms on lenvatinib plasma trough concentrations in Japanese patients with thyroid cancer
por: Ozeki, Tomoko, et al.
Publicado: (2019)

Neuronal Cell Sheets of Cortical Motor Neuron Phenotype Derived from Human iPSCs
por: Suzuki, Noboru, et al.
Publicado: (2017)

Simultaneous quantification method for 5-FU, uracil, and tegafur using UPLC-MS/MS and clinical application in monitoring UFT/LV combination therapy after hepatectomy
por: Shiraiwa, Ken, et al.
Publicado: (2021)

Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study
por: Casadei-Gardini, Andrea, et al.
Publicado: (2022)

Lenvatinib activates anti-tumor immunity by suppressing immunoinhibitory infiltrates in the tumor microenvironment of advanced hepatocellular carcinoma
por: Yamauchi, Masami, et al.
Publicado: (2023)

Differences in the Intestinal Microbiome Associated with Diarrhea during Lenvatinib Treatment for Hepatocellular Carcinoma
por: Inukai, Yosuke, et al.
Publicado: (2023)

Bifidobacteria Abundance-Featured Gut Microbiota Compositional Change in Patients with Behcet’s Disease
por: Shimizu, Jun, et al.
Publicado: (2016)

Lenvatinib recruits cytotoxic GZMK+CD8 T cells in hepatocellular carcinoma
por: Yamada, Tomoharu, et al.
Publicado: (2023)

Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma
por: He, Min-Ke, et al.
Publicado: (2021)

Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study
por: Ueshima, Kazuomi, et al.
Publicado: (2019)

Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma
por: Amioka, Kei, et al.
Publicado: (2022)

Lenvatinib: T3 thyrotoxicosis: case report
Publicado: (2021)

Thrombotic microangiopathy associated with lenvatinib therapy
por: Contreras Angulo, Macarena, et al.
Publicado: (2023)

Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan
por: Kobayashi, Masahiro, et al.
Publicado: (2019)

Efficacy and safety of eltrombopag in Japanese patients with chronic liver disease and thrombocytopenia: a randomized, open-label, phase II study
por: Kawaguchi, Takumi, et al.
Publicado: (2012)

Lenvatinib in Advanced Radioiodine-Refractory Thyroid Cancer - A Retrospective Analysis of the Swiss Lenvatinib Named Patient Program
por: Balmelli, Catharina, et al.
Publicado: (2018)

Rechallenge with Lenvatinib after Refractoriness to Initial Lenvatinib Followed by Sorafenib in a Patient with Metastatic Papillary Thyroid Carcinoma
por: Takinami, Masaki, et al.
Publicado: (2020)

Significant elevation of free itraconazole concentration at onset of adverse effects: A case report
por: Tanaka, Ryota, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_36jd3k7igv0tchajgkchb23jmf